^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Follicular Lymphoma
    Regimen: (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/20/2021
    Excerpt:
    Follicular Lymphoma: FIRST-LINE THERAPY…Preferred Regimens…CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + Obinutuzumab or rituximab
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    11/26/2020
    Excerpt:
    ...rituximab in combination with CHOP or bendamustine should be used if complete remission and long PFS are the therapeutic goals [I, B]. If there is evidence of more aggressive clinical course, obinutuzumab/rituximab-CHOP should be applied....Consensus-driven recommendations- For stage III/IV FL with high tumor burden and >65 years and <65 years immunoCHT such as...R-CHOP [I,A].
    DOI:
    10.1016/j.annonc.2020.11.008